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Abstract 
Two different pathological mechanisms have been suggested to underlie adult-onset leukoencephalopathy 
with axonal spheroids (ALAS). Pathological studies have suggested that ALAS involves primary axonopathy with 
secondary demyelination. However, the identification of mutations in Colony Stimulating Factor 1 Receptor 
(CSF1R), important for microglial survival, has suggested that ALAS is a microgliopathy. This study examines the 
correlation between microglial changes and axonopathy in ALAS. A total of 6 ALAS cases were studied. White 
matter lesions were classified into three evolving stages: 1) numerous axonal spheroids among well-myelinated 
fibers; 2) moderate loss of myelinated fibers with or without axonal spheroids; and 3) a leukodystrophy-like 
pattern of severe confluent axonal and myelin loss. Axonal spheroids and ramified microglia were semi-
quantified and the lesions were assigned a score of 0–3. We found a strong correlation between the prepon-
derance of axonal spheroids and ramified microglial loss. All areas with a predominance of axonal spheroids 
showed a near-complete absence of ramified microglia, which was also apparent in small cortical and white 
matter lesions. In contrast, some areas with no ramified microglia showed no axonal pathology. Our findings 
support the suggestion that ramified microglia loss precedes axonal spheroids formation. This observation will 
help to better understand the pathogenesis of ALAS and suggests a protective role of microglia. 
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Two different pathological mechanisms have 
been suggested to underlie adult-onset leu-
koencephalopathy with axonal spheroids (ALAS). 
Pathological studies have proposed a primary axo-
nopathy with secondary demyelination (1, 2), while 
genetic/molecular studies have identified a muta-
tion in a gene important for microglial function 
and, hence, implied that ALAS is a microgliopathy 
(3). Moreover, a recent pathological study has 
identified a microglial morphological alteration (i.e. 
“dysplastic” microglia) as the pathological correlate 
for microgliopathy (4). ALAS is also known by other 
names in the literature with most common ones 
being hereditary diffuse leukoencephalopathy with 
spheroids (HDLS) and adult-onset leukoencephalo-
pathy with axonal spheroids and pigmented glia 
(ALSP).  
Recent advances in our understanding of the 
biology and functions of microglia have demon-
strated both its beneficial and harmful effects on 
various diseases (5). Investigating the relationship 
between microgliopathy and axonopathy in the 
pathogenesis of ALAS may provide better insight 
into the role of microglia in this disease. Recent 
attempts to explain the pathogenesis yielded dif-
ferent conclusions: 1) generalized colony stimulat-
ing factor 1 receptor (CSF1R) signaling impairment 
in CD68-immunopositive microglia is followed by 
multifocal axonal degeneration (6); 2) increase in 
ionizing calcium-binding molecule 1 (IBA1) and 
CD68-immunopositive cell numbers precedes ax-
onal pathology (7); 3) uneven distribution of IBA1-
immunopositive cells in the white matter precludes 
any firm conclusions regarding the role of these 
cells in the pathology (4); and 4) CSF1R mutations 
lead to aberrant microglia density and distribution, 
and regional loss of microglia (8). 
In this study, we investigated the relationship be-
tween axonal pathology and microglial changes in 
ALAS using the pathological staging system of ALAS 
proposed by Alturkustani et al. (1). This system 
focuses on the specific stages of the lesions rather 
than the overall pathological stage of the entire 
case at a point in time (7) and should provide a 
more precise correlation.  
Materials and Methods 
A formal autopsy consent was provided in all 
cases and the Western University research ethics 
board approved the study. A total of 6 ALAS cases 
were studied. Four cases were described before 
(cases 1–4) (1). Two additional cases of ALAS were 
referred to the London Health Sciences Center la-
boratory in 2013–2017. 
The brains were fixed and prepared as de-
scribed before (1). Representative samples were 
submitted for microscopic examination and stain-
ing, and immunostaining procedures were per-
formed as described previously (1). These proce-
dures include Luxol fast blue (LFB) with hematoxy-
lin and eosin (HE) staining. For immunohistochem-
istry, the primary antibodies used were anti-
amyloid precursor protein (APP; Chemicon, Temec-
ula, CA), anti-phosphorylated neurofilament 
(SMI31; Covance, Berkeley, CA), and anti-glial fibril-
lary acidic protein (Dako, Carpinteria, CA). Mouse 
monoclonal anti-HLA-DR antibody (1:200; clone 
CR3/43; Dako, Carpinteria, CA) was used to label 
microglial cells. Anti-ionized calcium binding adap-
tor molecule 1 (IBA1) antibody (1:500, 019-19741, 
WAKO) was stained in Dr. V. Wee Yong’s laboratory 
(Calgary, Canada) following their previously pub-
lished protocol (9). 
The white matter lesions were classified into 
three evolving stages, as discussed in our previous 
work (1): 1) numerous axonal spheroids within 
well-myelinated fibers; 2) moderate loss of myelin-
ated fibers with or without axonal spheroids; and 3) 
a leukodystrophy-like pattern with severe conflu-
ent axonal and myelin loss. Digital images of LFB-
HE, APP, HLA-DR, IBA1, and SMI31 staining slides 
were obtained using the Aperio system. Particular 
areas of interest were demarcated on the comput-
er screen of these digital images. At least five areas 
for each pathological stage from each case were 
examined. The pathological features, regardless of 
the size of the lesion, defined the pathological 
stages. Any lesion can range from very small areas 
(usually in stage 1 pathology) to very large (com-
mon in stage 3 pathology). A single area in the 
white matter could contain more than one patho-
logical stage. 
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Axonal spheroids and the HLA-DR-expressing 
cells were semi-quantified (see supplemental figure 
1) and lesions were assigned a score of 0–3. The 
scoring for axonal spheroids was as follows: 0 = 
absence of axonal spheroids; 1 = few axonal sphe-
roids (1–2/high power field; HPF); 2 = moderate 
number of axonal spheroids (3–5/HPF); and 3 = 
frequent axonal spheroids (6 or more/HPF). For the 
HLA-DR and/or IBA1-expressing cells, we subdivid-
ed them into ramified-phenotype and amoeboid-
phenotype. Their numbers were scored in the fol-
lowing manner: 0 = no HLA-DR staining; 1= few cells 
(1–9/HPF); 2 = moderate number of cells (10–
19/HPF); and 3 = frequent cells (20 or more/HPF). 
Several morphological shapes of microglia 
have been identified (10). However, for the sake of 
simplicity, in this study we divided microglia into 
two different types: 1) ramified microglia with a 
small cell body with branching processes radiating 
from the cell bodies, including a broad spectrum of 
reactive microglial shapes with varying lengths and 
thicknesses of processes and different cell body 
dimensions; and 2) amoeboid microglia with a mac-
rophage-like or amoeboid phenotype characterized 
by a round cytoplasm with no processes. 
The white matter from the same autopsy tis-
sue in the areas adjacent to the affected white 
matter and separate from it was used as control 
tissue to confirm the reliability of the immunostains 
(i.e. internal positive control) used in this study. As 
the autopsy brain tissue from relatively normal 
cases was not expected to show axonal spheroids, 
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The clinical information for the first four cases 
has been discussed before (1) and is summarized in 
table 1. In general, clinical presentations were de-
pendent on the location of the white matter areas 
affected, which were preferentially frontotemporal. 
Case 5 was a 57-year-old female who had a rapid 2-
year progression of neurobehavioral symptoms 
(self-neglect and apathy) and seizures until death. 
She had a sister with cognitive impairments, but 
slower progression. Both patients had a previously 
unreported variant of CSF1R (c.2563 C>T) mutation 
(11). Their mother had a history of early-onset de-
mentia. Case 6 was a 38-year-old female with a 
rapid decline in cognition and short- and long-term 
memory impairment. She was placed in a nursing 
home as she required assistance for daily life activi-
ties and died two years after the initial presenta-
tion. Her first-degree relatives had a positive histo-
ry of dementia. She had another novel variant of 
CSF1R (c.2377A>G) mutation. The CSF1R gene mu-
tational analysis for the first 4 cases was unsuccess-
ful as the quality of the DNA extracted from fixed 
tissue was inadequate, as discussed before (1). 




A%3EG). Various software tools including DANN 
(score 0.9991 and 0.9989, respectively), Muta-
tionTaster (disease causing), FATHMM (Damaging), 
FATHMM-MKL (Damaging), MetaSVM (Damaging), 
and MetaLR (Damaging) predicted pathogenicity, 
which was supported by locations within the pro-
tein kinase functional domain. 
Antibodies against HLA-DR and IBA1 are con-
sidered the most sensitive markers for microglia as 
both stain all the morphological forms of activated 
microglia, phagocytic, and dystrophic microglia (5). 
Although IBA1 may be considered to be a more 
sensitive marker for these microglia by some au-
thors (5), we found that HLA-DR is more sensitive 
for microglia staining in the white matter and com-
parable to IBA1 staining in the gray matter. IBA1 
immunostaining also showed background staining, 
requiring careful examination to distinguish the 
immunopositive cells from the background (see 
supplemental figure 2). This resulted in an inferior 
quality of images for analysis. The following results 
were confirmed by both HLA-DR and IBA1 im-
munostains but are better demonstrated with the 
HLA-DR images, which we will utilize in the rest of 
this article. 
HLA-DR and IBA1 immunostaining showed a 
wide variation of microglial morphology in both 
gray and white matter in all cases. Microglial pro-
cesses showed variations in number (single to mul-
tiple), thickness, and length. Some of the processes 
showed discontinuous staining and some areas 
showed only fragmented processes, which could be 
considered dysplastic (4) or dystrophic (5). Micro-
glia with fragmented processes were observed 
along with those with intact processes in areas of 
normal-appearing white matter. This wide morpho-
logical variation made it difficult to correlate be-
tween microglial morphology and axonal spheroids. 
Therefore, as indicated in Materials and Methods, 
we only considered microglia with the amoeboid 
phenotype (i.e. globular cytoplasm with no pro-
cesses) as a separate form of microglia. All other 
morphological variations of microglia, including 
those with fragmented processes, were considered 
ramified/reactive microglia. 
Using this simplified categorization of HLA-DR 
and IBA1-expressing cells (ramified vs. amoeboid 
phenotype), we consistently detected the following 
changes in all 6 cases (table 2): the white matter 
lesions classified as stage 1 pathology showed well-
myelinated areas with moderate to frequent (score 
2–3) axonal spheroids and a consistent loss of HLA-
DR-expressing cells with ramified morphology 
(score 0) in close proximity to the axonal spheroids 
(Figure 1A–F). Some areas had a few (score 1) HLA-
DR-expressing microglia with amoeboid phenotype, 
while others showed none (score 0). This may indi-
cate that these areas had a slightly longer patholo-
gy duration than the areas without these cells. The 
white matter adjacent to the affected areas was 
unremarkable, with no axonal spheroids, no pig-
mented microglia, or other abnormality (Figure 
1G). However, HLA-DR immunostaining showed 
denser forms of “ramified” microglia (Figure 1H).
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The remarkable association of axonal spheroids and 
the complete loss of ramified microglia was also 
evident in the affected cortex (Figure 2A–D). This 
association was apparent even in a very small area 
of cortical involvement, while the immediately ad-
jacent area showed ramified microglia (Figure 2E–
H). 
In stage 2 pathology, white matter showed 
reduced myelin staining (Figure 3A–B), a variable 
number of axonal spheroids ranging from none to 
frequent (score 0–3), moderate to frequent amoe-
boid microglia (score 2–3), and none to few rami-
fied microglia. According to the distribution of ax-
onal spheroids, these areas were subclassified into 
three components: 1) Areas with axonal spheroids 
(score 1–3), showing no ramified microglia (score 
0), but moderate to frequent amoeboid microglia 
(score 2–3). These areas may represent an “ac-
tive/ongoing injury.” The white matter surrounding 
these areas showed widespread dense ramified 
microglia (score 3), while cells with amoeboid-
phenotype were present in the central area (score 
2–3), and the surrounding white matter (Figure 3C–
F), used as an internal control for HLA-DR im-
munostaining. 2) Areas with no axonal spheroids 
(score 0), few-moderate amoeboid microglia (score 
1–2), and no ramified microglia (score 0; Figure 3G–
H). These can be considered “susceptible areas” 
and can have a different degree of myelinated ax-
ons loss. 3) Areas with no axonal spheroids (score 
0), few-moderate amoeboid microglia (score 1–2), 
and none to few ramified microglial cells (score 1). 
These may represent areas of secondary axonal 
degeneration. 
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Figure 1. Microglia and axonal spheroids in stage 1 pathology. All images in this figure are representative of case 2. (A) Normal-
appearing white matter with frequent spheroids inside the rectangular inset (LFB-HE; scale bar: 500 µm). (B) Higher magnification of (A) 
shows many spheroids and no pigmented microglia (LFB-HE; scale bar: 50 µm). (C) APP immunostaining highlights frequent axonal sphe-
roids inside the rectangular inset (APP; scale bar: 500 µm). (D) Higher magnification of (C) (APP; scale bar: 100 µm). (E) The affected area 
in (C) with many axonal spheroids in the white matter and a small area of adjacent cortex shows a nearly complete loss of HLA-DR-
expressing ramified microglia (inside the polygonal inset) and only a few scattered HLA-DR-expressing amoeboid-phenotype cells. The 
adjacent normal-appearing areas show an increased expression of HLA-DR-positive ramified microglia (HLA-DR; scale bar: 1 mm). (F) 
Higher magnification of (E) (HLA-DR; scale bar: 500 µm). (G) Normal-appearing white matter adjacent to the affected area shows no 
recognizable abnormalities (LFB-HE; scale bar: 50 µm). (H): HLA-DR immunostaining shows a frequent expression of HLA-DR-
immunopositive ramified microglia (HLA-DR; scale bar: 50 µm).  
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Figure 2. Cortical involvement in ALAS. All images in this figure are representative of case 6. (A) Focal involvement of the upper cortex 
with frequent axonal spheroids (inside ellipse) compared to the cortex on the right side. The underlying U-fibers are also affected (LFB-
HE; scale bar: 500 µm). (B) Higher magnification of (A) from the cortical area inside the ellipse (LFB-HE; scale bar: 50 µm). (A) and (B) 
represent an inset (higher magnification of the upper rectangle) in Figure 4A. (C) HLA-DR immunostaining shows a complete focal loss of 
staining in the area with frequent axonal spheroids (inside ellipse) (HLA-DR; scale bar: 500 µm). (D) Higher magnification of (C) to high-
light the presence of axonal spheroids (note the arrows) associated with a complete absence of HLA-DR-expressing ramified microglia 
(HLA-DR; scale bar: 50 µm). (E): A small cortical area (inside the rectangle) with frequent axonal spheroids (APP; scale bar: 500 µm). (F) 
Higher magnification of (E) (APP; scale bar: 50 µm.). (G) HLA-DR loss is limited to the very small affected area (inside the rectangle), 
while the surrounding cortical areas show HLA-DR-expressing ramified microglia (HLA-DR; scale bar: 500 µm). (H) Higher magnification 
of (G) (HLA-DR; scale bar: 200 µm).  
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Figure 3. Microglia and axonal spheroids in stage 2 pathology. All images in this figure are representative of case 5. (A) Decreased mye-
lin staining in the deep subcortical white matter (mostly inside the inset) compared to the surrounding subcortical U-fibers (LFB-HE; 
scale bar: 500 µm). (B) Higher magnification of (A) (LFB-HE; scale bar: 200 µm). (C) The area showing decreased myelin staining in (A) 
shows a complete loss of HLA-DR-expressing ramified microglia (mostly inside the inset), but moderate numbers of HLA-DR-
immunopositive cells with amoeboid phenotype. The adjacent white matter shows frequent HLA-DR-expressing ramified microglia (HLA-
DR; scale bar: 500 µm). (D) Higher magnification of (C) (scale bar: 200 µm). (E) APP-immunopositive axonal spheroids are limited to the 
area (mostly inside the inset) showing an extensive loss of ramified microglia and presence of HLA-DR expressing cells with amoeboid 
phenotype (APP; scale bar: 500 µm). (F) Higher magnification of (E) (APP; scale bar: 200 µm). (G): Another area with decreased myelin 
staining due to a prominent loss of myelinated fibers but without axonal spheroids (LFB-HE; scale bar: 50 µm). (H) Scattered HLA-DR-
immunopositive cells with amoeboid phenotype in the same area (HLA-DR; scale bar: 100 µm).  
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In stage 3 pathology, the white matter showed 
a marked loss of myelinated axons and a relative 
preservation of the subcortical U-fibers (Figure 4A), 
which was classified as a “leukodystrophy-like” 
pattern. Although the white matter in this area as a 
whole was considered stage 3 pathology, HLA-DR 
immunostaining highlighted different patterns of 
staining (Figure 4B), which allowed us to appreciate 
variations in the preservation of the white matter 
and the distribution of HLA-DR-expressing cells in 
stage 3. We could observe areas of compact neu-
ropil in the background, few small myelinated ax-
ons, a moderate number of oligodendrocytes, and 
mild to moderate gliosis (Figure 4C–E) along with 
rarefied areas showing a marked loss of oligoden-
drocytes and moderate gliosis (Figure 4G). HLA-DR 
immunostaining highlighted dense (score 3) rami-
fied microglia in the areas showing higher white 
matter preservation and in the relatively preserved 
myelinated subcortical U-fibers (Figure 4B, D, F), 
while rarefied areas showed no ramified microglia 
(score 0) and a few to moderate (score 1–2) amoe-
boid microglia (Figure 4H). Axonal spheroids were 
absent (score 0) in most areas, yet scattered and 
rare (score 1) in others. 
Unfortunately, the imaging characteristics are 
not available for the radiological-pathological cor-
relation. In general, stage 3 pathology, which de-
notes long-standing lesions, are prominent in 
frontal and temporal lobes, less prominent in parie-
tal lobes, and rare in occipital lobes. 
Discussion 
Axonal spheroids and ramified microglia 
We found a strong association between the 
presence of axonal spheroids and a complete loss 
of ramified microglia in all pathological stages of 
ALAS lesions. This association was also apparent in 
very small areas with frequent axonal spheroids 
and in focal cortical lesions, strengthening the reli-
ability of the findings. Although this was a semi-
quantitative study, our findings demonstrate a 
strong correlation between the complete absence 
of ramified microglia (score 0) and the presence of 
axonal spheroids in affected areas. This finding 
could be considered “quantitative”, as score 0 de-
notes a complete absence of the ramified micro-
glia. In stage 3, the presence of ramified microglia 
was associated with areas of better white matter 
preservation. These findings provide a link between 
pathological features observed (i.e. axonopathy) 
and the genetic abnormality identified (i.e. micro-
gliopathy) in ALAS, supporting the beneficial effects 
of the reactive ramified microglia in maintaining 
axonal integrity. 
CSF1R and ALAS 
Identifying CSF1R mutations as the underlying 
genetic abnormality in ALAS suggested microgliopa-
thy as the underlying abnormality (3, 12) in ALAS. 
As it is the most common mutation in ALAS, Konno 
et al. proposed the term “CSF1R-related leu-
koencephalopathy” for this entity (13). As the 
pathological features are the gold standard for 
ALAS diagnosis and not all ALAS cases have CSF1R 
alterations, this term would be specific to cases 
with confirmed CSF1R mutations only and would 
not be suitable for all ALAS cases. AARS2 mutations 
have been described in cases suspected to repre-
sent ALAS, including one case with biopsy findings 
supportive of this diagnosis (14). However, we con-
cur with Konno et al. that “further studies, includ-
ing detailed analyses of autopsied brains, are re-
quired to characterize AARS2 associated leu-
koencephalopathy” (13). 
CSF1R is a tyrosine kinase receptor whose sig-
naling is fundamental for microglial survival (15). 
Two different mechanisms have been proposed for 
CSF1R mutations to affect the function of microglia 
in patients with ALAS: 1) Haploinsufficiency mecha-
nism that results in a loss of function of CSF1R (8, 
16, 17), and 2) a dominant-negative model (18). It 
is still unclear what the lost functions are or what is 
constitutive of the dominant-negative effect on the 
microglia. Oosterhof et al. concluded that the hap-
loinsufficiency resulted in the maldistribution of 
microglia that leads to their local loss (8). Their 
recent work showed that homozygous mutations in 
CSF1R could result in the complete absence of mi-
croglia in pediatric-onset leukodystrophy (19). Our 
results confirmed the regional loss of ramified mi-
croglia in ALAS and found that the axonal pathology 
is mostly limited to these areas, supporting the 
importance of microglia in ALAS’ pathogenesis and 
suggesting a protective role of ramified microglia.
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Figure 4. Microglia and axonal spheroids in stage 3 pathology. All images in this figure are representative of case 6. (A) Marked loss of 
myelinated fibers in the deep white matter with relative preservation of the subcortical U-fibers (LFB-HE; scale bar: 5 mm). A higher 
magnification of the area inside the upper rectangle can be seen in Figure 2. (B) Variable degree of HLA-DR expression in the subcortical 
deep white matter with multifocal areas containing HLA-DR-expressing ramified microglia. These areas are found mainly in the subcorti-
cal U-fibers and small foci of the adjacent white matter. The deeper white matter shows only scattered HLA-DR-expressing ramified 
microglia (HLA-DR; scale bar: 5 mm). (C) Higher magnification of the area within the lower rectangle outlined in (A). The deep white 
matter shows a variable loss of myelinated fibers. Areas of prominent loss show marked rarefaction, while areas with better preserved 
myelinated fibers in the center show a more compact parenchyma (LFB-HE; scale bar: 500 µm). (D) A better-preserved central area in 
(C) shows a marked expression of HLA-DR ramified microglia, while rarefied areas show only scattered HLA-DR-expressing ramified 
microglia and moderate to frequent HLA-DR-expressing cells with amoeboid phenotype (HLA-DR; scale bar: 500 µm). (E) Higher magnifi-
cation of the better-preserved area in (C). Although there is a marked loss of myelinated fibers, a few scattered myelinated fibers re-
main, neuropil appears more compacted, and the loss of oligodendrocytes is mild to moderate (LFB-HE; scale bar: 50 µm). (F) Higher 
magnification of the central area in (D) (HLA-DR; scale bar: 50 µm). (G) The rarefied white matter areas show only occasional myelinated 
fibers, the neuropil is rarefied and mainly formed by astrocytic processes, while oligodendrocytes loss is moderate to severe (LFB-HE; 
scale bar: 50 µm). (H) HLA-DR immunostaining of the area in (G) shows mainly microglia with the amoeboid phenotype (HLA-DR; scale 
bar: 100 µm).  
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Morphological correlation of microglia and ax-
onal degeneration 
Tada et al. described “dysplastic” microglia in 
brain samples from six patients with confirmed 
CSF1R mutations (4). These dysplastic microglia 
were interpreted as the morphological manifesta-
tion of the CSF1R mutation, but no association with 
axonal spheroids was established. In this study, we 
observed various reactive microglia morphologies, 
including some that can be considered “dys-
trophic”/“dysplastic”. However, the significance of 
these changes was hard to interpret and to corre-
late with the pathology. A different sequence of 
events in the pathogenesis of ALAS has been sug-
gested. Riku et al. concluded that broad microglial 
impairment and low CSF1R expression on microglia 
preceded multifocal axonal degeneration (6). 
Meanwhile, Oyanagi et al. concluded that microglia 
proliferation preceded axonal swelling and loss. 
This conclusion suggests that microglial prolifera-
tion rather than loss leads to pathology (i.e. micro-
glia is harmful and not beneficial; 7), which stands 
in contrast to our conclusions. 
In this study, we concluded that microglial loss 
preceded axonal degeneration based on the follow-
ing observations: 1) There is a consistent complete 
loss of ramified microglia (by both HLA-DR & IBA1 
immunostains) in all areas with axonal spheroids. 
As we did not observe any area with axonal sphe-
roids to have reactive ramified microglia, it is un-
likely that axonal spheroids precede microglia loss. 
2) There is a presence of “susceptible areas” in 
stage 2 (i.e. areas with no ramified microglia and no 
axonal spheroids). Ramified microglia loss in these 
areas are significant as reactive microglia should be 
present in areas with white matter pathology. The 
presence of microglia with amoeboid phenotypes 
in these areas confirm the reliability of microglia 
immunostaining in these sections. 3) There is a 
presence of morphologically abnormal microglia in 
normal-appearing white matter. Tada et al., using 
ultrastructural examination, considered these dys-
plastic (4). 
Methodological differences between the stud-
ies might explain the difference in conclusions be-
tween this study and previous studies. In this study 
we described the correlation between the axonal 
spheroids and ramified microglia in each lesion 
based on its stage rather than the overall brain 
pathology used by Oyanagi et al. The latter system 
is useful for the correlation of clinical findings and 
the duration of pathology, while the former is more 
suitable to evaluate the mechanisms of a multifocal 
disease showing lesions with different pathological 
stages. Similar limitations may also apply to the 
conclusion drawn by Tada et al. on the microglial 
distribution in ALAS patients. They described spatial 
differences in microglia distribution with areas 
showing reduced numbers of microglia and others 
showing microgliosis in both the cortex and the 
white matter. They concluded that this differential 
distribution interferes with any meaningful quanti-
tative statistical study of microglia depending on 
the area examined (4). This conclusion is valid if all 
lesions are studied together as one stage but not 
specifically for the stage of the individual lesion as 
analyzed in this study. We found that this spatial 
distribution did correlate with the axonal pathology 
in ALAS. 
The second significant difference between the 
previous studies and our study is that the other 
authors did not distinguish between ramified mi-
croglia and those with amoeboid phenotype. Many 
morphological variations of microglia have been 
identified (10). Although morphology is not a relia-
ble predictor of function, microglia with amoeboid 
phenotype is an exception as it is consistently asso-
ciated with phagocytosis (10). Therefore, we sug-
gest that at least the microglia with amoeboid phe-
notype should be distinguished from other pheno-
types. 
Microglia functions and pathology 
Microglia are regarded as immune cells of the 
central nervous system (CNS) and play a role in 
tackling viruses, phagocytosis, and as antigen-
presenting cells (10, 20). Recently, additional func-
tions have been demonstrated, such as active sur-
veillance of synaptic integrity, regulation of brain 
development and potentially in blood vessel for-
mation (10, 20). Microglia have been considered 
both pro-inflammatory and anti-inflammatory as 
well as neurotoxic and neuroprotective depending 
on their functional profiles (10, 20). The beneficial 
effects of microglia described include limiting the 
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effects of cerebral ischemia in animal models since 
their absence through CSF1R blockade results in 
increased infarct size (21–23), while microglial re-
population reverses this effect (23). Microglial loss 
due to absence of CSF1R affects brain development 
and results in olfactory deficits in mice (24). Most 
harmful effects of microglia are associated with the 
concept of neuroinflammation, especially in multi-
ple sclerosis (25), and after traumatic brain injury 
(26, 27). However, the term and the concept of 
neuroinflammation should be used with extreme 
caution, as suggested by Graeber and Streit (20). 
Microglia and axonal pathology 
There are only few studies that deal with the 
association between the axonal pathology and mi-
croglial reaction. In the experimental micropig 
model for mild traumatic brain injury, Lafrenaye et 
al. found that activated microglia contacted the 
proximal segments of injured axons (i.e. axonal 
spheroids) within 6 hours of the induced injury 
(28). Lafrenaye et al. suggested that microglia acti-
vation is beneficial and may enhance axonal regen-
eration through this contact (29). In a human study, 
microglia activation and microglia nodules were 
associated with axonal swelling in the perilesional 
white matter. These changes were demonstrated in 
the periplaque white matter lesions in multiple 
sclerosis, in white matter areas adjacent to infarcts, 
and in traumatic brain injury (30). In this study, the 
preferred hypothesis was that microglial reac-
tion/nodules resulted in the axonal damage (30). 
However, no evidence of the timing of the events 
was provided to support this conclusion. Both stud-
ies (29, 30) showed the close association of reactive 
microglia to the axonal spheroids in affected white 
matter areas. The interpretation is quite different 
as the latter study suggested that neuroinflamma-
tion (defined as a microglial reaction) resulted in 
the axonal pathology (30), while the former study 
found that microglia reaction is secondary to axon-
al injury and suggested a neuroprotective function 
to these activated microglia. Our study described a 
different association between the axonal pathology 
and the ramified microglia, which, to our 
knowledge, has not been described before, and in 
which axonal spheroids were associated with loss 
of ramified microglia. The remarkable restriction of 
axonal spheroids to these areas, best appreciated 
in the small early lesions (i.e. stage 1 pathology), 
suggests that the loss of microglia is protective in 
preventing this pathology.     
Pathogenesis of ALAS 
The focus on the pathogenesis of ALAS has 
changed in the literature since the recognition of 
CSF1R mutations in ALAS. Previous pathological 
studies focused on the role of axonal pathology in 
the pathogenesis. The most relevant conclusions 
were: 1) The pathological features of the affected 
white matter suggest that the main pathological 
process is axonal degeneration with secondary 
demyelination (1); 2) the recurring or ongoing na-
ture of the pathology is supported by the gradual 
progression of the white matter pathologic pro-
cesses (31, 32); and 3) a possible role of hypoxic-
ischemic injuries in the pathogenesis of ALAS (32, 
33). 
Studies after the discovery of CSF1R mutations 
in ALAS focused on the effect of these mutations 
on microglia and the morphological changes of 
microglia in ALAS. The most relevant conclusions 
from these studies include: 1) CSF1R mutations can 
affect microglia through loss of function (haploin-
sufficiency model; 17) or dominant-negative effect 
(18); 2) demonstration of dystrophic microglia as 
the possible pathological correlate of these muta-
tions (4); 3) change of microglia density precedes 
the white matter pathology, but with contradicting 
results. Oyanagi et al. proposed that microglia pro-
liferation preceded axonal degeneration (7), while 
Oosterhof et al. found that microglia loss preceded 
it (8); and 4) CSF1R haploinsufficiency may lead to 
the maldistribution of microglia and result in the 
regional loss (8). 
There are many different ways to associate 
the previous observations and conclusions about 
the lesions in ALAS with meaningful pathogenesis. 
We propose the following pathogenesis: microglia 
loss precedes the axonal pathology and most likely 
represents an early stage of the pathology. Howev-
er, it is still unclear what causes axonal injuries to 
develop in these restricted areas (and how), and 
whether this progression occurs with time only 
(e.g. aging process) or if an additional etiology (e.g. 
hypoperfusion) is required. 
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Axonal injuries that result in axonal spheroids 
formation have many causes, including hypoxic-
ischemic, metabolic, toxic, and traumatic causes. In 
previous studies of ALAS, evidence of oxidative 
stress caused by hypoxic-ischemic etiology was 
presented (32, 33) and this may represent possible 
additional etiological factors in the pathogenesis of 
ALAS. The effects of hypoxic-ischemic injury de-
pend on the severity and the duration of the hypox-
ic-ischemic events. As there are no morphological 
features of moderate to severe hypoxic-ischemic 
injury in ALAS, and the axonal injuries are limited to 
areas of microglia loss, we concluded that this 
should be viewed as a mild form of injury. One pos-
sible cause of mild hypoxic-ischemic events that 
occur with aging is age-related cerebral hypoperfu-
sion (34), which could potentially explain the de-
layed presentation and progression of lesions in 
ALAS. We emphasize that this is speculative, and 
not a conclusion of this study, but it might be an 
explanation of the observed correlation between 
the axonal pathology and the microglial loss. How-
ever, this proposed pathogenesis indicates that 
progression of ALAS is potentially preventable 
through: 1) replacement of the lost ramified micro-
glia to prevent further damage through their pro-
tective function, and 2) improving or preventing 
the reduced cerebral blood flow associated with 
aging. The first suggestion supports the promising 
results from allogeneic haematopoietic stem cell 
transplantation (to repopulate the microglial niche) 
in patients with ALAS (35, 36). The second sugges-
tion is currently unpractical, even in the animal 
model, but this may change in the future. 
Limitation of the study 
The major limitation of this study was the ina-
bility to test for CSF1R mutation from the paraffin 
sections in four of the six cases. However, the his-
topathological diagnosis of ALAS is reliable and 
considered the current gold standard as new muta-
tions in different genes are being discovered in 
ALAS. The pathological features of all cases were 
similar and the characteristic three pathological 
stages were present in all cases. There was no dif-
ference in the morphological features between 
cases with confirmed CSF1R alterations (case 5 and 
6), and cases with no genetic confirmation (cases 
1–4). The association of microglia distribution to 
the axonal spheroids and the pathological stages 
were similar in all cases, as well (table 2). Our re-
sults and conclusions in this study (i.e. the correla-
tion between microglia loss and axonal spheroids) 
are based on the pathological findings only, regard-
less of the underlying genetic alterations. As such, 
this limitation should not depreciate our results 
and conclusions. However, it restricted our ability 
to study the correlation between CSF1R mutation 
and the morphological changes. 
Conclusions 
The main finding of this study is a multifocal 
loss of ramified microglia in ALAS. This loss was 
seen in the affected areas of all pathological stages 
and best correlated with the presence of axonal 
spheroids. The presence of dense ramified micro-
glia was associated with better preservation of the 
white matter. We concluded that ramified micro-
glia most likely have a protective function for the 
white matter and that their absence contributes to 
axonal pathology observed in ALAS. These findings 
will contribute to a better understanding of the 
pathogenesis of ALAS and the protective roles of 
microglia, thus providing possible areas of interven-
tion to prevent the progression of the disease.  
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